We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Celgene Settles Patent Royalty Case for $198.5 Million
Celgene Settles Patent Royalty Case for $198.5 Million
Celgene will pay $198.5 million to settle a case alleging the company failed to pay royalties on patents covering the multiple myeloma drugs Revlimid and Pomalyst/Imnovid.